Funding For Programs

Promiliad has been exceptionally successful in receiving highly competitive awards from the National Institutes of Health for our antibiotic development programs. To date we have been awarded multiple phase I and phase II SBIR/STTR awards, totaling over $6 million in non-dilutive funds.

Year Title Collaboration With
2020 Single application thixotropic antibiotic delivery systems for Otitis externa The University Of Montana
2019 Novel antibacterial agents derived from natural products The University Of Montana
2018 Single application thixotropic antibiotic delivery systems for Otitis externa The University Of Montana
2016 Novel antibacterial agents derived from natural products The University Of Montana
2013 Development of stable isosteres of dihydrofolate reductase inhibitors as antibacterial agents -
2010 Potent antifolates as new therapeutics for MRSA The University of Connecticut
2009 The identification of novel negative allosteric modulators of the nicotinic receptor The Ohio State University
2009 New antibiotics targeting fatty acid biosynthesis The University of Connecticut
2008 Isoindolinones as antibacterial agents Ohio University
2006 Natural feedstocks for diversity-oriented synthesis Dartmouth College
2006 Potent and selective DHFR inhibitors for treating cryptosporidiosis Dartmouth College
2005 Fermentation initiated antibiotic syntheses Ohio University
2004 Natural feedstocks for diversity-oriented synthesis University of Florida